NASDAQ
07.10.25 | 21:58
2,255 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.10. | C4 Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| C4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 01.10. | C4 Therapeutics, Inc.: C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma | 64 | GlobeNewswire (Europe) | WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science... ► Artikel lesen | |
| 23.09. | C4 Therapeutics stock price target raised to $10 by Wells Fargo on positive data | 10 | Investing.com | ||
| 23.09. | C4 Therapeutics: Wells Fargo verdoppelt Kursziel nach positiven Studiendaten | 4 | Investing.com Deutsch | ||
| 22.09. | Forecasting The Future: 4 Analyst Projections For C4 Therapeutics | 3 | Benzinga.com | ||
| 22.09. | C4 Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 20.09. | Myelom-Medikament von C4 Therapeutics zeigt 50-prozentige Ansprechrate in Studie | 1 | Investing.com Deutsch | ||
| 20.09. | C4 Therapeutics Reports Promising Phase 1 Results For Cemsidomide In R/R Multiple Myeloma | 1 | RTTNews | ||
| 20.09. | C4 Therapeutics' myeloma drug shows 50% response rate in trial | 1 | Investing.com | ||
| 20.09. | C4 Therapeutics, Inc.: C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 16.09. | Barclays bestätigt "Overweight"-Rating für C4 Therapeutics | 1 | Investing.com Deutsch | ||
| 16.09. | C4 Therapeutics stock rating reiterated as Overweight by Barclays | 3 | Investing.com | ||
| 16.09. | Why C4 Therapeutics Stock Crushed the Market on Monday | 2 | The Motley Fool | ||
| 15.09. | Stephens-Upgrade beflügelt C4 Therapeutics-Aktie mit über 125 % Kurspotenzial | 5 | Investing.com Deutsch | ||
| 15.09. | C4 Therapeutics stock surges after Stephens upgrade signals upside | 4 | Investing.com | ||
| 04.09. | C4 Therapeutics, Inc.: C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration | 281 | GlobeNewswire (Europe) | WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science... ► Artikel lesen | |
| 04.09. | C4 Therapeutics stock initiated with Buy rating at Guggenheim on myeloma drug potential | 2 | Investing.com | ||
| 03.09. | C4T to host webcast on cemsidomide multiple myeloma trial data | 2 | Investing.com | ||
| 03.09. | C4 Therapeutics, Inc.: C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting | 6 | GlobeNewswire (USA) | ||
| 07.08. | C4 Therapeutics GAAP EPS of -$0.37 | 14 | Seeking Alpha |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 2,020 | -1,94 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Inducement Grant Under Inducement Plan | PLYMOUTH MEETING, Pa., Oct. 2, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| OCUGEN | 1,559 | +2,90 % | Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $7.5 millionPotential sales milestones of $180 million or more in first 10 years of commercializationRoyalties equaling 25%... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,914 | -0,21 % | Cardiff Oncology nach Daten-Dip: Jetzt kaufen? | Cardiff Oncology legt seine lang erwarteten Krebs-Daten vor und der Aktienkurs fährt Achterbahn: Bietet sich für Anleger ein neues Trading-Fenster, oder lässt man jetzt besser die Finger von dem Titel?... ► Artikel lesen | |
| CELLDEX THERAPEUTICS | 22,400 | -0,88 % | Celldex Therapeutics stock rating reiterated at Buy by H.C. Wainwright | ||
| COHERUS ONCOLOGY | 1,486 | +0,95 % | Coherus Oncology: Nach der Rallye folgt der Durchbruch? | Die Aktie von Coherus Oncology hat in den vergangenen Monaten deutlich an Dynamik gewonnen. Mit über 60 Prozent Kursplus seit April 2025 rückt das Unternehmen ins Rampenlicht - getragen von wachsenden... ► Artikel lesen | |
| NEOVACS | 0,150 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 18.07.2025 | The following instruments on XETRA do have their first trading 18.07.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 18.07.2025
Aktien
1 KYG7388C1033 Qunabox Group Ltd.
2... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 20,480 | 0,00 % | Arcturus Therapeutics Holdings Inc. - 8-K, Current Report | ||
| ULTRAGENYX | 25,800 | +0,78 % | Ultragenyx Pharmaceutical Inc.: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | NOVATO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for... ► Artikel lesen | |
| GYRE THERAPEUTICS | 6,200 | -0,80 % | Gyre Therapeutics Inc.: Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update | Net income of $1.6 million and $5.3 million for the three and six months ended June 30, 2025, respectively; reaffirms full-year revenue guidance of $118-128 million Ping Zhang, Executive... ► Artikel lesen | |
| BIOMEA FUSION | 1,840 | 0,00 % | Biomea Fusion, Inc.: Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations | Icovamenib showed a sustained treatment benefit at Week 52 (9 months past the end of treatment) in the severe insulin-deficient diabetes patient population taking one or more antihyperglycemic medications... ► Artikel lesen | |
| JANUX THERAPEUTICS | 22,640 | 0,00 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
| GOSSAMER BIO | 2,158 | +0,28 % | Respira Therapeutics, Inc.: Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital | - Transaction designed to accelerate development of RT234 (vardenafil Inhalation powder), an investigational first-in-class, as-needed (PRN) treatment for PAH and... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 6,300 | 0,00 % | Sagimet Biosciences Inc.: Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination | Dosing has successfully commenced with healthy volunteersPrimary endpoints for the Phase 1 trial include safety, tolerability, and pharmacokinetic (PK) profile of the combinationTopline data are anticipated... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 8,320 | 0,00 % | 4D Molecular Therapeutics, Inc. - 8-K, Current Report | ||
| TENAYA THERAPEUTICS | 1,765 | 0,00 % | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially... ► Artikel lesen |
C4 THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,255 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu C4 THERAPEUTICS INC finden Sie auf Wallstreet Online.